Search Within

Hebert Alberto Vargas Alvarez

  1. "Howard Scher"
Formats
  1. Journal Article (16)
  2. Meeting Abstract (3)
  3. Review (1)
Groups
  1. Department of Medicine (20)
  2. Genitourinary Oncology Service (20)
  3. Molecular Imaging and Therapy Service (20)
  4. Solid Tumor Oncology Division (20)
  5. GSK Faculty (12)
  6. Epidemiology and Biostatistics (11)

More Groups

People
  1. Howard Scher (20)
  2. Michael Morris (12)
  3. Hedvig Hricak (7)
  4. Steven Larson (6)
  5. Andreas Wibmer (5)
  6. Daniel Danila (5)

More People

Years
  1. 2024 (1)
  2. 2023 (1)
  3. 2022 (1)
  4. 2021 (1)
  5. 2019 (2)
  6. 2018 (4)

More Years

Publications
  1. JAMA Oncology (3)
  2. Journal of Clinical Oncology (2)
  3. Journal of Nuclear Medicine (2)
  4. Radiology (2)
  5. Urology (2)
  6. Annals of Oncology (1)

More Publications

Publishers
  1. Elsevier Science, Inc. (4)
  2. American Medical Association (3)
  3. American Society of Clinical Oncology (3)
  4. Radiological Society of North America, Inc. (2)
  5. Society of Nuclear Medicine (2)
  6. American Association for Cancer Research (1)

More Publishers

Results (20)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Convergent evolution of BRCA2 reversion mutations under therapeutic pressure by PARP inhibition and platinum chemotherapy
    Journal Article

    Walmsley, C. S.; Jonsson, P.; Cheng, M. L.; McBride, S.; Kaeser, C.; Vargas, H. A.; Laudone, V.; Taylor, B. S.; Kappagantula, R.; Baez, P.; more...
    npj Precision Oncology (2024)

    Fulltext@MSK | Save
  • Automated analysis of FDG-PET/CT imaging to monitor heterogeneous disease response in metastatic castration-resistant prostate cancer
    Meeting Abstract

    Barnett, E.; Woo, S.; Perk, T. G.; Munian-Govindan, R.; Lokre, O.; Gajar, R. N.; Erazo, T.; Carbone, E.; Morris, M. J.; Vargas, H. A.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Correlation between imaging-based intermediate endpoints and overall survival in men with metastatic castration-resistant prostate cancer: Analysis of 28 randomized trials using the Prostate Cancer Clinical Trials Working Group (PCWG2) criteria in 16,511 patients
    Journal Article

    Woo, S.; Suh, C. H.; Wibmer, A. G.; Becker, A. S.; Teo, M. Y.; Gönen, M.; Hricak, H.; Scher, H. I.; Morris, M. J.; Vargas, H. A.
    Clinical Genitourinary Cancer (2022)

    Fulltext@MSK | Save
  • Quantification of metastatic prostate cancer whole-body tumor burden with (18)F-FDG PET parameters and associations with overall survival after first-line abiraterone or enzalutamide: A single-center retrospective cohort study
    Journal Article

    Wibmer, A. G.; Morris, M. J.; Gonen, M.; Zheng, J.; Hricak, H.; Larson, S.; Scher, H. I.; Vargas, H. A.
    Journal of Nuclear Medicine (2021)

    Fulltext@MSK | Save
  • Comparison of magnetic resonance imaging-stratified clinical pathways and systematic transrectal ultrasound-guided biopsy pathway for the detection of clinically significant prostate cancer: A systematic review and meta-analysis of randomized controlled trials
    Review

    Woo, S.; Suh, C. H.; Eastham, J. A.; Zelefsky, M. J.; Morris, M. J.; Abida, W.; Scher, H. I.; Sidlow, R.; Becker, A. S.; Wibmer, A. G.; more...
    European Urology Oncology (2019)

    Fulltext@MSK | Save
  • Analysis of the prevalence of microsatellite instability in prostate cancer and response to immune checkpoint blockade
    Journal Article

    Abida, W.; Cheng, M. L.; Armenia, J.; Middha, S.; Autio, K. A.; Vargas, H. A.; Rathkopf, D.; Morris, M. J.; Danila, D. C.; Slovin, S. F.; more...
    JAMA Oncology (2019)

    Fulltext@MSK | Save
  • Consensus on molecular imaging and theranostics in prostate cancer
    Journal Article

    Fanti, S.; Minozzi, S.; Antoch, G.; Banks, I.; Briganti, A.; Carrio, I.; Chiti, A.; Clarke, N.; Eiber, M.; De Bono, J.; more...
    Lancet Oncology (2018)

    Fulltext@MSK | Save
  • Reproducibility and repeatability of semiquantitative (18)F-fluorodihydrotestosterone uptake metrics in castration-resistant prostate cancer metastases: A prospective multicenter study
    Journal Article

    Vargas, H. A.; Kramer, G. M.; Scott, A. M.; Weickhardt, A.; Meier, A. A.; Parada, N.; Beattie, B. J.; Humm, J. L.; Staton, K. D.; Zanzonico, P. B.; more...
    Journal of Nuclear Medicine (2018)

    Fulltext@MSK | Save
  • Drug development for noncastrate prostate cancer in a changed therapeutic landscape
    Journal Article

    Teo, M. Y.; O'Shaughnessy, M. J.; McBride, S. M.; Vargas, H. A.; Scher, H. I.
    Nature Reviews Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Positron emission tomography/computed tomography-based assessments of androgen receptor expression and glycolytic activity as a prognostic biomarker for metastatic castration-resistant prostate cancer
    Journal Article

    Fox, J. J.; Gavane, S. C.; Blanc-Autran, E.; Nehmeh, S.; Gonen, M.; Beattie, B.; Vargas, H. A.; Schoder, H.; Humm, J. L.; Fine, S. W.; more...
    JAMA Oncology (2018)

    Fulltext@MSK | Save